



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.07
Trade Time:	10:06 AM ET 12/11/17
Change:	0.01 <span style="color: green;">▲</span> (0.485%)
Day Range	2.04 - 2.09
52-Week Range	1.27 - 7.10
Volume	51,881


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 12/11/17**  
[Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium](#)
- 11/09/17**  
[Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference](#)
- 11/08/17**  
[Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer](#)
- 11/06/17**  
[Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 10/13/17**  
[Rexahn Announces \\$8 Million Registered Direct Offering](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- 02/24/17**  
[Annual Report \(10-K\)](#)
- 02/24/17**  
[Proxy Statement \(DEF 14A\)](#)
- 11/03/17**  
[Quarterly Report \(10-Q\)](#)
- 08/04/17**  
[Quarterly Report \(10-Q\)](#)
- 05/03/17**  
[Quarterly Report \(10-Q\)](#)